Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to -$257.7 million.

  • Nurix Therapeutics' Cash from Investing Activities rose 336.54% to $50.5 million in Q3 2025 from the same period last year, while for Aug 2025 it was $6.7 million, marking a year-over-year increase of 105.10%. This contributed to the annual value of -$257.7 million for FY2024, which is 477.32% down from last year.
  • According to the latest figures from FY2024, Nurix Therapeutics' Cash from Investing Activities is -$257.7 million, which was down 477.32% from $68.3 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Cash from Investing Activities registered a high of $68.3 million during FY2023, and its lowest value of -$257.7 million during FY2024.
  • Over the past 3 years, Nurix Therapeutics' median Cash from Investing Activities value was $27.2 million (recorded in 2022), while the average stood at -$54.1 million.
  • Per our database at Business Quant, Nurix Therapeutics' Cash from Investing Activities tumbled by 3,093.69% in 2020 and then surged by 151.13% in 2023.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Cash from Investing Activities stood at -$254.4 million in 2020, then surged by 57.45% to -$108.3 million in 2021, then skyrocketed by 125.12% to $27.2 million in 2022, then spiked by 151.13% to $68.3 million in 2023, then slumped by 477.32% to -$257.7 million in 2024.